Neuropeptide Y receptor type 2 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Neuropeptide Y receptor type 2 shows clinical signal disease relevance led by obesity. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P49146. Start with obesity, then reuse UniProt P49146 as the stable protein anchor across project notes and exports.
Start with obesity, then reuse UniProt P49146 as the stable protein anchor across project notes and exports.
Neuropeptide Y receptor type 2 shows clinical signal disease relevance led by obesity. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with obesity because it currently carries clinical signal support. Linked drugs include PEPTIDE YY HUMAN (3-36). This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyNeuropeptide Y receptor type 2
Review this target as Neuropeptide Y receptor type 2, mapped to UniProt P49146. Sequence length is 381 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Neuropeptide Y receptor type 2 as ChEMBL target CHEMBL4018, mapped to UniProt P49146. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Neuropeptide Y receptor type 2 is the right protein anchor across sources, using UniProt P49146 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why obesity is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Neuropeptide Y receptor type 2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P49146 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Neuropeptide Y receptor type 2 |
| UniProt Accession | P49146 |
| Component Type | Protein |
| Sequence Length | 381 aa |
Neuropeptide Y receptor type 2
Review this target as Neuropeptide Y receptor type 2, mapped to UniProt P49146. Sequence length is 381 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Neuropeptide Y receptor type 2 shows clinical signal disease relevance led by obesity. 1 more disease program remain visible in the same review block.
Start review with obesity because it currently carries clinical signal support. Linked drugs include PEPTIDE YY HUMAN (3-36). This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5420881 | 10.79 | EC50 | 0.0163 | Preclinical |
| CHEMBL267633 | 10.55 | Ki | 0.028 | Preclinical |
| CHEMBL438945 | 10.55 | IC50 | 0.028 | Preclinical |
| CHEMBL3559801 | 10.2 | EC50 | 0.0631 | Preclinical |
| CHEMBL4090092 | 10.17 | EC50 | 0.068 | Preclinical |
| CHEMBL267633 | 10.16 | IC50 | 0.069 | Preclinical |
| CHEMBL269503 | 10.15 | IC50 | 0.07 | Preclinical |
| CHEMBL438945 | 10.12 | Ki | 0.076 | Preclinical |
| CHEMBL4207076 | 9.96 | EC50 | 0.11 | Preclinical |
| CHEMBL4208191 | 9.96 | EC50 | 0.11 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 99 | 146 | 6.2 |
| cell-based format | 52 | 247 | 7.7 |
| assay format | 5 | 69 | 8.5 |
| cell membrane format | 2 | 7 | 5.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 34 | 388 | 7.2 |
| assay format | 13 | 73 | 6.1 |
| single protein format | 1 | 4 | 6.1 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 1 | 0 | — |